Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Triepitopic antibody fusions inhibit cetuximab-resistant BRAF and KRAS mutant tumors via EGFR signal repression.

Journal of molecular biology - 28 Sept 2012

Spangler Jamie B, Manzari Mandana T, Rosalia Elizabeth K, Chen Tiffany F, Wittrup K Dane

Abstract excerpt

Dysregulation of epidermal growth factor receptor (EGFR) is a hallmark of many epithelial cancers, rendering this receptor an attractive target for cancer therapy. Much effort has been focused on the development of EGFR-directed antibody-based therapeutics, culminating in the clinical approval of the drugs cetuximab and panitumumab. Unfortunately, the clinical efficacy of these drugs has been disappointingly low,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cetuximab

Share to Down-Regulation

Share to Fibronectins

Share to HCT116 Cells

Share to HT29 Cells

Share to ras Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 22706026
DOI: 10.1016/j.jmb.2012.06.014
PMCID: PMC4041985

Genes

EGFR
BRAF
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Triepitopic antibody fusions inhibit cetuximab-resistant BRAF and KRAS mutant tumors via EGFR signal repression.PMID 22706026Read ↗

Impact of Cell-surface Antigen Expression on Target Engagement and Function of an Epidermal Growth Factor Receptor × c-MET Bispecific Antibody.Semantic proximity Read ↗

Multiparatopic antibodies overcome tyrosine kinase inhibitor resistance by inducing lysosomal degradation of EGFR mutants.Semantic proximity Read ↗

Novel antibody cocktail therapy targeting extracellular tumor-specific mutations to treat triple-negative breast cancerSemantic proximity Read ↗

Multiparatopic antibodies overcome tyrosine kinase inhibitor resistance by inducing lysosomal degradation of EGFR mutantsSemantic proximity Read ↗

Differential and synergistic effects of epidermal growth factor receptor antibodies on unliganded ErbB dimers and oligomers.Semantic proximity Read ↗

A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors.Semantic proximity Read ↗

Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapySemantic proximity Read ↗

T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells.Semantic proximity Read ↗

The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer.Semantic proximity Read ↗

A Biparatopic Antibody That Modulates MET Trafficking Exhibits Enhanced Efficacy Compared with Parental Antibodies in MET-Driven Tumor ModelsSemantic proximity Read ↗

A novel bispecific EGFR/Met antibody blocks tumor-promoting phenotypic effects induced by resistance to EGFR inhibition and has potent antitumor activity.Semantic proximity Read ↗

Novel antibody cocktail therapy targeting extracellular tumor-specific mutations to treat EMT6 cell line-derived triple-negative breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.